We have previously described a method for adoptive immunotherapy of cancer based on antigen-specific Th1 cells. However, efficient induction of antitumor responses using Th1 cells remains a formidable challenge, especially for MHC class II-negative tumors. In the present study, we sought to develop a novel strategy to eradicate established tumors of the MHC class II-negative, OVA-expressing EG-7. Tumor-bearing mice were intradermally (i. 
Tetramer staining. We used a slightly modified version of the original manufacturer's instructions to stain cells with OVA-MHC tetramers. Lymphocytes isolated from tumor DLN or the tumor site were washed twice with phosphate-buffered saline and stained with 3.3 µL/mL of OVA-MHC tetramers per 1x10 6 cells at 4°C for 15min, followed by staining with FITC-labeled anti-CD8 mAb. The cells were washed again with phosphate-buffered saline and analyzed by FCM. As described previously (21), tetramer-blocking assays for determining the fine MHC-restricted peptide antigen specificity was carried out by co-culture of 51 Cr-labeled target cells with effector cells, which were prelabeled with tetramer reagent.
Flow cytometric analysis.
Detailed procedures for staining and sorting have been described previously (18) . Fluorescence data were collected on a FACSCalibur (Becton Dickinson, San Jose, CA, USA), and analyzed using CellQuest software (BD Biosciences, Mountain View, CA, USA).
mAbs used for experiments are listed in the reagent section.
Th1 cell adjuvant therapy.
A total of 2x10 6 MHC class II-negative EG-7 cells were i.d. Cr-labeled target cells were incubated with CD8 + CTL pretreated with OVA-tetramer, which blocks the recognition of antigen by CTL. CD8 + T cells were enriched by MACS system according to the manufacturer's protocol. The percent cytotoxicity was calculated as described previously (29).
Immunohistochemical analysis. Snap-frozen, Tissue-Tek-embedded lymph nodes (five for each group) were cut at 5-7mm, fixed for 10min in cold acetone and used for immunohistochemical analysis. We used an already established double-immunofluorescence staining protocol for Foxp3 and CD4 (30). Briefly, the primary antibodies were diluted in 1% BSA (polyclonal rabbit antibody against murine Foxp3 at a concentration of 5 μg/mL and rat anti-mouse CD4 antibody from BD Pharmingen (diluted 1：500). The secondary antibody was applied at a 1： 500 dilution (anti-rat IgG-Alexa 546, anti-rabbit IgG-Alexa 488; Alexa, Leiden, The Netherlands).
Finally, the samples were analyzed with Olympus FV500 confocal laser scanning microscope system (Olympus Optical, Tokyo, Japan). were co-injected with OVA antigen, the CFSE dilution profiles indicated that Th1 cells had undergone multiple rounds of cell division in tumor DLN (Fig. 3A-b) . Such extensive proliferation of (3 days after 1 st therapy) though Th1 cell proliferation was observed at later time (data not shown).
Results

Eradication
Treatment of tumor-bearing mice with Th1 cells alone caused no significant cell proliferation of CFSE-labeled Th1 cells (Fig. 3A-a) . These data indicate that tumor DLN are critical lymphoid organs for the migration and activation of injected Th1 cells in our immunotherapy model. cell adjuvant therapy were completely cured from the tumor (Fig. 1) . The improved antitumor response observed in these mice was strongly dependent on activation of CD8 + Ag-specific CTL, because OVA/H-2K b specific CTL activity was enriched in CD8 + T cells ( 
